AAPM Task Group 119 has produced quantitative confidence limits as baseline expectation values for IMRT commissioning. A set of test cases was developed to assess the overall accuracy of planning and delivery of IMRT treatments. Each test uses contours of targets and avoidance structures drawn within rectangular phantoms. These tests were planned, delivered, measured, and analyzed by nine facilities using a variety of IMRT planning and delivery systems. Each facility had passed the Radiological Physics Center credentialing tests for IMRT. The agreement between the planned and measured doses was determined using ion chamber dosimetry in high and low dose regions, film dosimetry on coronal planes in the phantom with all fields delivered, and planar dosimetry for each field measured perpendicular to the central axis. The planar dose distributions were assessed using gamma criteria of 3%/3 mm. The mean values and standard deviations were used to develop confidence limits for the test results using the concept confidence limit = /mean/ + 1.96sigma. Other facilities can use the test protocol and results as a basis for comparison to this group. Locally derived confidence limits that substantially exceed these baseline values may indicate the need for improved IMRT commissioning.

The use of a multileaf collimator in the dynamic mode to perform intensity modulated radiotherapy became a reality at our institution in 1995. Unlike treatment with static fields using a multileaf collimator, there are significant dosimetric issues which must be assessed before dynamic therapy can be implemented. We have performed a series of calculations and measurements to quantify head scatter for small fields, collimator transmission, and the transmission through rounded leaf ends. If not accounted for, these factors affect the delivered dose to the prostate by 5%-20% for a typical plan. Data obtained with ion chambers and radiographic film are presented for both 6 and 15 MV x-ray beams. The impact on the delivered dose of the mechanical accuracy of the multileaf collimator, achieved during leaf position calibration and maintained during dose delivery, is also discussed.

No abstract

No abstract

No abstract

It has been shown that intensity-modulated fields have the potential to deliver optimum dose distributions, i.e., high dose uniformity in the target and lower doses in the surrounding critical organs. One way to deliver such fields is by using dynamic multileaf collimation (DMLC). This capability is already available in research mode on some treatment machines. While much effort has been devoted to developing algorithms for DMLC, the mechanical reliability of this new treatment delivery mode has not been fully studied. In this work, we report a series of tests designed to investigate the mechanical aspects of DMLC and their implications on dosimetry. Specifically, these tests were designed to examine (1) the stability of leaf speed, (2) the effect of lateral disequilibrium on dose profiles between adjacent leaves, (3) the significance of acceleration and deceleration of leaf motion, (4) the effect of positional accuracy and rounded-end of the leaves, and (5) create a simple test pattern that may serve as a basis for routine quality assurance checks. Results of these tests are presented. The implications on dosimetry and consideration for the design of leaf motion are discussed.

No abstract

The delivery of intensity modulated radiation therapy ͑IMRT͒ using dynamic multileaf collimation ͑DMLC͒ accounts for about 40% of all treatments on eight multileaf collimator ͑MLC͒-equipped linacs currently at the central and satellite facilities of the Memorial Sloan Kettering Cancer Center ͑MSKCC͒. These numbers have been steadily growing for the past 6 years. Treatment with IMRT has been used for a variety of cancers, including tumors of the prostate, head and neck, breast, paraspinal regions, and brain. To ensure that patients are treated in an accurate, efficient, and safe manner, we have developed a comprehensive QA program including mechanical quality assurance, which monitors known potential weaknesses in the MLC device itself, and verification of patientspecific treatments, to confirm the reliability of new software and to identify errors introduced through human interaction with individual patient's plans. This paper presents the reasoning, methodology, and results for mechanical, dosimetric, and electronic tests that are conducted at MSKCC.